In addition, elevated GRX expression has been observed in NSCLC cells resistant to gefitinib, a commonly used epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor [81]. This evidence concerns the gene GLRX and non-small cell lung carcinoma.